Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.04. | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.03. | Earnings call: Marpai reports mixed Q4 and FY 2023 financial results | 2 | Investing.com | ||
26.03. | Marpai, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
26.03. | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | Marpai GAAP EPS of -$0.65 misses by $0.38, revenue of $8.71M beats by $0.3M | 1 | Seeking Alpha | ||
26.03. | Marpai Reports Fourth Quarter And Full Year 2023 Financial Results | 48 | PR Newswire | Full Year Benefit of Maestro Acquisition and Q4 Corrective Actions Driving Financial Improvement
TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI)... ► Artikel lesen | |
13.03. | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.03. | Marpai reports Q4 results | 1 | Seeking Alpha | ||
06.03. | Marpai Announces Preliminary Unaudited Financial Results For Fourth Quarter And Full Year 2023 | 71 | PR Newswire | Full Year Impact of Maestro Acquisition and Q4 Corrective Actions Driving Improvement
TAMPA, Fla., March 6, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent... ► Artikel lesen | |
05.03. | Marpai secures deal to expand in the Southeast market | 2 | Investing.com | ||
05.03. | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.02. | Marpai secures new financing terms and $1.7 million funding | - | Investing.com | ||
08.02. | Marpai, Inc. - 8-K, Current Report | - | SEC Filings | ||
18.01. | Marpai CEO buys 1.1M shares of the company - filing | 1 | Seeking Alpha | ||
18.01. | Why Is Marpai (MRAI) Stock Up 27% Today? | 1 | InvestorPlace | ||
18.01. | Pre-market Movers: Marpai, Roma Green Finance, Newcourt Acquisition Corp., M.D.C. Holdings, Plug Power | 587 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.10 A.M. ET).In the Green Marpai, Inc. (MRAI) is up over 28% at $1.09.
Roma... ► Artikel lesen | |
17.01. | Marpai, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.01. | Marpai appoints John Powers as its CEO | 1 | Seeking Alpha | ||
13.12.23 | Marpai, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.12.23 | Marpai regains compliance with Nasdaq minimum bid price requirement | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 27,210 | +0,11 % | Cardiol Therapeutics, Bayer AG, Fresenius Aktie - wer ist der Trendsetter im Gesundheitsmarkt von morgen? | Die Gesundheitsbranche ist ein lukratives Segment für risikobewusste Anleger. Die globale Marktgröße für Gesundheitsdienstleistungen wird voraussichtlich bis 2028 eine jährliche Wachstumsrate (CAGR)... ► Artikel lesen | |
TELADOC HEALTH | 12,126 | -0,23 % | Why Teladoc Health Stock Dived on Friday | ||
NUGEN MEDICAL DEVICES | 0,077 | +0,52 % | NuGen Medical Devices Inc.: NuGen Announces Debt Settlement and Amendments to Care4Pharma Share Purchase Agreement | Toronto, Ontario--(Newsfile Corp. - April 15, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces that it has agreed to settle an aggregate of €275,000 of indebtedness... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 1,504 | +5,47 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE... ► Artikel lesen | |
CO-DIAGNOSTICS | 1,050 | +0,96 % | Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results | SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic... ► Artikel lesen | |
IMAGIN MEDICAL | 0,001 | 0,00 % | XFRA DPD3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILIMAGIN MEDICAL INC.... ► Artikel lesen | |
LOGICMARK | 0,780 | +5,41 % | LogicMark Inc reports results for the quarter ended in December - Earnings Summary | ||
INVO BIOSCIENCE | 0,990 | +1,01 % | Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers | ||
SIEMENS HEALTHINEERS | 52,94 | +1,22 % | DZ BANK stuft Siemens Healthineers auf 'Halten' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Siemens Healthineers vor Zahlen von 52 auf 53 Euro angehoben und die Einstufung auf "Halten" belassen. Analyst Sven Kürten erwartet... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 37,420 | -0,98 % | Fresenius Medical Care: Was war das denn gestern? | Mit einem Kursanstieg um satte 6,44 Prozent wurde Fresenius Medical Care am Montag klarer Tagessieger im MDAX. Aber was war da los, was trieb die Aktie so stark? Vorab-Ergebnisse zum ersten Quartal... ► Artikel lesen | |
CARL ZEISS MEDITEC | 100,30 | +1,31 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec vor Zahlen für das zweite Geschäftsquartal auf "Underweight" mit einem Kursziel von 70 Euro belassen. Seine... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 51,83 | -0,86 % | PROCEPT BioRobotics Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million | SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
GERRESHEIMER | 100,50 | +1,31 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Gerresheimer von 126 auf 128 Euro angehoben und die Einstufung auf "Buy" belassen. Es werde wohl noch ein Quartal dauern... ► Artikel lesen | |
PROGYNY | 32,040 | -1,42 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
MOBILE-HEALTH NETWORK SOLUTIONS | 23,890 | +0,46 % | APAC Telehealth Leader MNDR Expects Revenue Growth in H12024 vs H12023 | SINGAPORE, April 22, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) ("Mobile-Health" or the "Company"), a pioneering Asia-Pacific ("APAC") telehealth provider, today provided... ► Artikel lesen |